Premium
Helix BioPharma Corp (HBP)
TSX
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
RICHMOND HILL, Ontario, July 30, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer...
RICHMOND HILL, Ontario, July 13, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
RICHMOND HILL, Ontario, June 26, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in...
NEW YORK, June 22, 2020 (GLOBE NEWSWIRE) -- Proactive, the digital financial news organization, will be showcasing four rising stars of the life sciences industry with its first North American...
RICHMOND HILL, Ontario, June 22, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
RICHMOND HILL, Ontario, June 11, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
RICHMOND HILL, Ontario, May 14, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
RICHMOND HILL, Ontario, April 02, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
RICHMOND HILL, Ontario, March 16, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer...
RICHMOND HILL, Ontario, March 12, 2020 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.02 | -2.12765957447 | 0.94 | 0.98 | 0.92 | 1194 | 0.97497656 | CS |
| 4 | 0 | 0 | 0.92 | 0.98 | 0.89 | 970 | 0.93717174 | CS |
| 12 | 0.12 | 15 | 0.8 | 1.06 | 0.57 | 8622 | 0.79816491 | CS |
| 26 | -0.23 | -20 | 1.15 | 1.34 | 0.5 | 7713 | 0.9276928 | CS |
| 52 | 0.02 | 2.22222222222 | 0.9 | 1.35 | 0.5 | 8574 | 0.96177359 | CS |
| 156 | -0.405 | -30.5660377358 | 1.325 | 1.5 | 0.5 | 12079 | 1.06795539 | CS |
| 260 | -5.53 | -85.7364341085 | 6.45 | 10.05 | 0.5 | 17169 | 2.19565152 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
